Access Statistics for Frank Lichtenberg

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia 0 0 0 14 0 1 3 124
Benefits and Costs of Newer Drugs: An Update 0 0 1 259 1 1 4 637
CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS 0 0 0 1 0 0 4 890
CROWDING OUT: THE IMPACT OF THE STRATEGIC DEFENSE INITIATIVE ON U.S. CIVILIAN R&D INVESTMENT AND INDUSTRIAL COMPETITIVENESS 0 0 0 0 0 0 1 883
Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 0 0 1 188 0 0 5 1,408
Computer Use and Productivity Growth in federal Government Agencies 0 0 0 0 0 0 2 1,405
Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act 0 0 0 147 1 3 15 739
Does foreign direct investment transfer technology across borders? 0 0 0 0 7 16 62 457
Errors of Measurement in Output Deflators 0 0 0 46 1 2 6 227
GOVERNMENT SUBSIDIES TO PRIVATE MILITARY R&D INVESTMEN: DOD'S IR&D POLICY 0 0 0 1 0 1 4 711
Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy 0 1 1 113 0 4 8 577
HOW ELASTIC IS THE GOVERNMENT'S DEMAND FOR WEAPONS? 0 0 0 0 0 1 6 380
Has medical innovation reduced cancer mortality? 0 0 0 66 0 1 9 202
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 0 0 0 40 1 1 7 191
How Elastic is the Government's Demand for Weapons? 0 1 1 27 0 2 4 219
How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 0 0 3 45 2 3 17 31
IR&D Project Data and Theories of R&D Investment 0 0 0 75 0 1 5 364
Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data 0 0 1 46 0 1 11 172
Importation and Innovation 0 0 0 58 0 3 8 304
Industrial De-Diversification and Its Consequences for Productivity 0 0 0 7 1 2 4 58
Industrial De-Diversification and its Consequences for Productivity 0 0 0 65 2 2 9 281
International R&D Spillovers: A Re-Examination 2 3 9 428 5 13 40 1,105
International R&D spillovers comment 0 0 0 10 1 4 12 159
Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability 0 0 0 20 0 1 6 138
Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients 0 0 1 22 0 1 6 52
Ownership Structure and Corporate Performance in Japan 0 0 0 227 1 3 9 723
Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009 0 0 5 85 1 2 16 162
Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 0 0 0 19 6 13 35 106
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth 0 0 1 363 0 3 11 1,589
Pharmaceutical innovation and the longevity of Australians: a first look 0 0 0 53 0 2 6 197
Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health" 0 0 0 217 0 1 10 878
Private Investment in R&D to Signal Ability to Perform Government Contracts 0 0 0 16 0 3 10 137
R and D and Productivity at the Industry Level: Is There Still a Relationship? 0 0 0 247 0 2 8 612
R&D Investment and International Productivity Differences 4 7 27 386 8 31 76 1,057
Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?" 0 0 2 13 0 1 6 110
Sources of U.S. Longevity Increase, 1960 -1997 1 1 2 58 1 3 4 597
Sources of U.S. Longevity Increase, 1960-1997 0 0 1 182 0 1 5 965
Spurious correlation in estimation of the health production function: A note 0 0 1 90 0 0 9 411
THE EFFECT OF TAKEOVERS ON THE EMPLOYMENT AND WAGES OF CENTRAL-OFFICE AND OTHER PERSONNEL 0 0 0 1 0 1 5 434
Technical Change, Learning, and Wages 0 0 0 36 1 1 7 159
The Allocation of Publicly-Funded Biomedical Research 0 1 1 47 0 3 4 486
The Allocation of Publicly-Funded Biomedical Research 0 0 0 68 0 0 3 1,020
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey 0 0 0 181 0 0 4 703
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey 0 0 0 61 0 1 6 382
The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence 1 2 3 112 1 4 9 463
The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France 0 0 1 59 0 2 7 217
The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry 0 0 0 281 0 2 13 890
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US 0 1 2 35 0 2 10 128
The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel 0 0 0 358 0 0 4 1,319
The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output 0 0 0 62 0 0 1 341
The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program 0 1 2 45 0 1 7 374
The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs 0 0 2 129 2 7 20 804
The Effect of New Drugs on Mortality from Rare Diseases and HIV 0 0 0 81 0 2 5 597
The Effect of New Political Administration on Federal Government Productivity and Employment 0 0 0 1 0 0 8 442
The Effect of New Political Administration on Federal Government Productivity and Employment 0 0 0 116 2 2 6 1,055
The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files 1 1 2 48 1 2 4 87
The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey 0 0 0 23 0 0 6 67
The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality 0 0 0 156 0 0 4 561
The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel 0 0 0 196 0 1 3 479
The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior 1 1 7 1,031 2 7 22 2,420
The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior 0 0 7 511 3 8 37 1,275
The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 0 0 0 10 0 0 3 40
The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 0 0 0 62 0 1 4 339
The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis 0 0 0 0 0 5 13 1,071
The Expanding Pharmaceutical Arsenal in the War on Cancer 0 0 1 113 0 0 7 399
The Impact and Organization of Publicly-Funded Research and Development in the European Community 0 0 0 115 0 0 6 881
The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data 0 0 0 2 3 4 7 42
The Impact of Hospital Quality-Related Practices on Health Outcomes 0 0 0 46 0 0 2 235
The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data 0 0 0 45 0 0 3 353
The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 0 0 9 0 0 9 24
The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 0 1 3 0 1 11 25
The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data 0 0 0 34 0 2 4 262
The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data 0 0 1 25 0 3 11 103
The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011 0 0 0 37 0 2 5 49
The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013 0 0 0 32 0 1 13 33
The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data 1 1 9 476 1 4 27 922
The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence 0 0 0 9 1 3 10 75
The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007 0 0 0 16 0 3 11 76
The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality 1 2 2 27 2 3 8 25
The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis 0 0 1 188 3 6 14 756
The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth 0 0 0 186 0 2 6 675
The expanding pharmaceutical arsenal in the war on cancer 0 0 0 119 0 0 10 527
The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis 0 0 1 22 0 1 14 54
The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001 0 0 0 201 0 1 3 599
Training, Tenure, and Productivity 0 0 0 61 0 0 5 233
USING LINKED CENSUS R&D-LRD DATA TO ANALYZE THE EFFECT OF R&D INVESTMENT ON TOTAL FACTOR PRODUCTIVITY GROWTH 0 0 2 375 1 2 14 857
Using Patents Data to Map Technical Change in Health-Related Areas 0 0 0 97 0 0 4 262
Total Working Papers 12 23 102 9,582 62 219 882 42,878


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia 0 0 2 17 4 7 16 167
Are the More Educated More Likely to Use New Drugs? 0 0 4 9 0 0 13 28
Benefits and costs of newer drugs: an update 0 0 4 86 0 0 13 397
Book Reviews 0 0 0 3 0 0 2 17
Changing market opportunities and the structure of R & D investment: The case of energy 0 0 0 10 0 0 4 61
Computer Use and Productivity Growth in US Federal Government Agencies, 1987-92 0 0 0 56 0 4 10 347
Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7 0 0 0 10 4 7 12 109
Contributions to Federal Election Campaigns by Government Contractors 0 0 0 18 2 2 4 295
Do (More and Better) Drugs Keep People Out of Hospitals? 0 2 4 272 1 4 10 642
Does Foreign Direct Investment Transfer Technology Across Borders? 1 4 18 591 8 23 77 1,552
Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization 0 0 2 56 0 0 10 188
Energy prices and induced innovation 0 0 0 54 0 0 3 103
Errors of Measurement in Output Deflators 0 0 0 0 1 2 7 237
Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data 0 1 1 21 0 1 4 142
Has Medical Innovation Reduced Cancer Mortality? 0 0 0 4 0 1 4 30
Has Pharmaceutical Innovation Reduced Social Security Disability Growth? 0 0 1 11 0 1 6 56
Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes? 0 0 0 20 0 0 6 90
Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003 0 0 0 26 0 1 8 262
How elastic is the government's demand for weapons? 0 0 0 13 0 1 5 127
IMPORTATION AND INNOVATION 0 0 0 28 0 1 6 316
IR & D project data and theories of R & D investment 0 0 0 6 0 1 5 49
Industrial de-diversification and its consequences for productivity 0 0 0 47 1 1 5 210
Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 2 4 10 208 3 8 30 707
Interindustry Technology Flows and Productivity Growth: A Re-examination 0 2 5 230 1 4 20 572
International R&D spillovers: A comment 2 9 16 339 5 18 45 850
Issues in measuring industrial R&D 0 0 1 26 0 0 2 74
Labour market institutions, liquidity constraints, and macroeconomic stability 0 0 0 9 0 0 8 123
Managerial ownership and firm performance: A re-examination using productivity measurement 1 4 8 161 1 7 22 371
Ownership structure and corporate performance in Japan 0 0 1 112 2 3 17 398
Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data 0 0 0 38 4 7 14 187
Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 0 0 2 10 4 23 36 74
Pharmaceutical Price Discrimination and Social Welfare 0 0 2 59 0 0 6 252
Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos 0 0 0 21 0 0 6 73
Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' 0 0 0 39 1 1 11 273
Productivity and Changes in Ownership of Manufactoring Plants 0 1 2 100 2 9 33 359
Rejoinder to comment by Maarten Vendrik 0 0 0 9 0 0 1 115
Sources of U.S. longevity increase, 1960-2001 2 2 11 132 3 8 40 428
Spurious correlation in estimation of the health production function: A note 0 0 2 55 1 8 35 351
THE EFFECT OF CONTROL CHANGES ON THE PRODUCTIVITY OF U.S. MANUFACTURING PLANTS 1 1 1 20 2 3 4 53
Testing the Convergence Hypothesis 2 2 13 335 4 8 65 1,271
The Comparative Advantage of Educated Workers in Implementing New Technology 4 8 28 763 7 26 98 3,586
The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry 0 2 6 23 0 7 26 186
The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment 0 2 5 202 3 7 28 577
The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel 0 1 1 4 1 2 4 417
The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files 0 0 2 35 1 5 16 190
The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003 0 0 1 1 0 2 9 49
The Effects of Medicare on Health Care Utilization and Outcomes 2 2 3 139 4 7 14 933
The Health Impact of, and access to, New Drugs in Korea 0 0 0 0 0 0 0 0
The Impact and Organization of Publicly-Funded Research and development in the European Community 0 0 0 2 15 17 36 65
The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries 0 1 1 2 0 1 14 19
The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis 0 0 2 2 1 2 10 10
The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015 0 0 6 11 2 3 27 38
The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 0 0 1 117 1 3 7 447
The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data 0 0 1 53 0 0 5 227
The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012 0 0 1 3 2 6 18 37
The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010 0 0 4 22 0 3 10 62
The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010 0 0 0 3 0 1 4 39
The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia 0 0 0 0 1 1 6 19
The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013 0 0 0 1 0 1 3 7
The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data 0 0 0 0 2 12 41 949
The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise 0 0 0 1 0 0 2 331
The Private R&D Investment Response to Federal Design and Technical Competitions 1 3 14 158 2 9 32 614
The Relationship between Federal Contract R&D and Company R&D 0 0 0 9 2 10 32 605
The benefits to society of new drugs: a survey of the econometric evidence 0 0 0 75 2 4 12 392
The burden of government:, Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95 0 0 0 2 0 0 1 47
The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004 0 0 0 81 1 2 5 439
The effect of new drug approvals on HIV mortality in the US, 1987-1998 0 0 0 16 0 0 2 107
The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010 0 0 0 5 1 3 8 37
The effects of leveraged buyouts on productivity and related aspects of firm behavior 2 2 21 531 5 16 88 1,404
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007 0 0 0 2 0 0 2 31
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013 0 0 0 1 2 3 10 23
The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009 0 0 1 25 1 6 18 102
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data 0 0 1 5 1 3 12 50
The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011 0 0 0 8 4 6 10 61
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence 0 0 0 5 0 1 8 40
The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007 0 0 0 5 0 2 16 118
The long-run impact of new medical ideas on cancer survival and mortality 0 0 0 0 2 2 4 4
The quality of medical care, behavioral risk factors, and longevity growth 0 0 0 32 2 7 27 226
Total Journal Articles 20 53 209 5,605 119 344 1,290 24,444


Chapter File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Are the More Educated More LIkely to Use New Drugs? 0 0 0 0 1 3 20 88
Economics of defense R&D 0 2 13 430 3 8 33 1,167
Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data 0 0 0 0 0 1 4 4
Pharmaceutical Knowledge-Capital Accumulation and Longevity 1 1 1 30 1 1 8 93
R&D and Productivity Growth at the Industry Level: Is There Still a Relationship? 1 8 22 128 2 21 55 318
The Allocation of Publicly Funded Biomedical Research 0 0 0 12 0 1 6 55
The Effects of Medicare on Health Care Utilization and Outcomes 0 0 2 341 1 4 20 4,155
The Impact of Biomedical Research on U.S. Cancer Mortality: A Bibliometric Analysis 0 0 0 5 0 0 4 33
The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 1 1 2 13 1 1 5 34
Total Chapters 3 12 40 959 9 40 155 5,947


Statistics updated 2020-07-04